
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is a rapidly growing company, with expanding product offerings and strong financial growth. Their recent achievements in developing blood tests for various diseases and gaining Medicare coverage show promise for further growth and profitability. Additionally, their partnerships and collaborations with other companies indicate a strong potential for future success.
Bears say
Natera is facing risks such as a potential decline in market share for its NIPT product and increased competition in the cancer recurrence monitoring market. Although the company raised its 2026 revenue and gross margin guides, they also increased their R&D spending to accelerate clinical studies for CRC screening, which may impact profitability. Furthermore, with other labs entering the large and underpenetrated MRD market, Natera may face challenges in proving the value of its tests and maintaining its first-mover advantage.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares